The initial public offering has gone ahead in the teeth of plunging markets, even though the price is well below its target. CIT begins trading today after being priced on MOnday at $23 a share, well under the $25 to $29 original target range. The 200m shares, underwritten by JP Morgan and Goldman Sachs, might have met an even worse reception had a rival billion-dollar IPO, Medco Health Solutions, not postponed its launch until later in the week.